One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study.

Sung Noh HongJoo Hye SongSung Jin KimYoon Ha ParkChang Wan ChoiJi Eun KimEun Ran KimDong Kyung ChangYoung-Ho Kim

Published in: Inflammatory bowel diseases (2023)

The SC IFX switch induced a higher 1-year durable remission rate than continuing IV IFX in patients with IBD during scheduled maintenance therapy, showing similar safety.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
stem cells
bone marrow
high glucose
rheumatoid arthritis
diabetic rats
systemic lupus erythematosus
disease activity
cell therapy
stress induced